TITLE

What are the current outcomes of advanced gastrointestinal stromal tumors: who are the long-term survivors treated initially with imatinib?

AUTHOR(S)
Rutkowski, Piotr; Andrzejuk, Jolanta; Bylina, Elżbieta; Osuch, Czesław; Świtaj, Tomasz; Jerzak vel Dobosz, Anna; Grzesiakowska, Urszula; Jurkowska, Monika; Woźniak, Agnieszka; Limon, Janusz; Dębiec-Rychter, Maria; Siedlecki, Janusz A.
PUB. DATE
December 2013
SOURCE
Medical Oncology;Dec2013, Vol. 30 Issue 4, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
92576942

 

Related Articles

  • Neoadjuvant Treatment of Rectal Gastrointestinal Stromal Tumors with Imatinib. Turner, Jacquelyn; Batus, Marta; Leslie, William; Coogan, Christopher; Saclarides, Theodore J. // American Surgeon;Aug2010, Vol. 76 Issue 8, pE110 

    A letter to the editor is presented which is concerned with two patients with gastrointestinal stromal tumors who were treated with imatinib.

  • Long-term efficacy of imatinib for treatment of metastatic GIST. Patel, Shreyaskumar // Cancer Chemotherapy & Pharmacology;Aug2013, Vol. 72 Issue 2, p277 

    Purpose: Imatinib is an effective and approved treatment for advanced gastrointestinal stromal tumor (GIST). Continuous imatinib treatment is recommended by current guidelines. This review summarizes the long-term efficacy and safety of imatinib for patients with metastatic GIST. Methods: Key...

  • Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors. Blay, J.-Y.; Pérol, D.; Le Cesne, A. // Annals of Oncology;Jul2012, Vol. 23 Issue 7, p1659 

    Background Imatinib is the standard of care for patients with advanced gastrointestinal stromal tumors (GIST). Design This article reviews recent data on the impact of imatinib treatment interruption and subsequent rechallenge in patients with advanced GIST. Results The randomized BFR14 trial...

  • Pathological complete response in advanced gastric stromal tumor after imatinib mesylate therapy: a case report.  // Journal of Medical Case Reports;2011, Vol. 5 Issue 1, p1 

    The article presents a case study of a 54-year-old Arab woman with a gastrointestinal stromal tumor. After neoadjuvant treatment with imatinib mesylate, she had a pathological complete response. It is mentioned that for patients who have advanced gastrointestinal stromal tumors, Imatinib...

  • Critical Update and Emerging Trends in Imatinib Treatment for Gastrointestinal Stromal Tumor. De Giorgi, Ugo; Pupi, Alberto; Turrisi, Gina; Montenora, Iolanda; Morini, Stefano; Fayyaz, Mozghan; De Simone, Michele; Fiorentini, Giammaria // Reviews on Recent Clinical Trials;Jan2007, Vol. 2 Issue 1, p43 

    The extraordinary success of imatinib in gastrointestinal stromal tumor (GIST) represents a model for molecularly targeted therapy of solid tumors. Research is currently going to identify the molecular basis of mechanisms of action and drug resistance. For the optimal management of the patients...

  • Considering the role of radiation therapy for gastrointestinal stromal tumor. Corbin, Kimberly S.; Kindler, Hedy L.; Liauw, Stanley L. // OncoTargets & Therapy;2014, Vol. 7, p713 

    Gastrointestinal stromal tumors (GISTs) are rare mesenchymal tumors arising in the gastrointestinal tract. Over the last decade, the management and prognosis of GISTs has changed dramatically with molecular characterization of the c-kit mutation and the adoption of targeted systemic therapy....

  • Pathologic complete response with neoadjuvant imatinib for locally advanced pelvic GIST. Azevedo, Carla; Paiva, Tadeu; Rossi, Benedito; Guimarães, Gustavo; Souza Begnami, Maria; Oliveira, Thiago; Barros e Silva, Milton; Fanelli, Marcello; Mello, Celso // International Journal of Clinical Oncology;Jun2011, Vol. 16 Issue 3, p279 

    There are few data that show pathologic complete response (pCR) to imatinib treatment in gastrointestinal stromal tumors (GISTs). We describe a case of a patient with pCR of a pelvic, locally advanced, high-risk GIST who was treated with neoadjuvant imatinib and ultimately underwent a...

  • Targeting Melanoma. Rowland, Belinda // Dermatology Times;May2003, Vol. 24 Issue 5, p44 

    Focuses on treatment options for melanoma. Absence of improvement in the therapy for advanced melanoma; Prolongation of survival rate; Approval of tyrosine kinase inhibitor imatinib mesylate for treating chronic myeloid leukemia and gastrointestinal stromal tumors.

  • Imatinib.  // Reactions Weekly;3/17/2012, Issue 1393, p24 

    The article describes the case of an elderly man who developed periorbital edema, musculoskeletal pain and neurologic manifestations secondary to long-term use of imatinib for metastatic gastrointestinal stromal tumor.

  • Radiotherapy in the treatment of gastrointestinal stromal tumor. Knowlton, Christin A.; Brady, Luther W.; Heintzelman, Rebecca C. // Rare Tumors;2011, Vol. 3 Issue 4, p111 

    Gastrointestinal stromal tumors (GISTs) are uncommon mesenchymal tumors of the gastrointestinal tract. Up to one-third of GISTs are malignant with a high rate of metastasis. Surgical resection is the mainstay of care for patients with resectable disease. Imatinib mesylate, a selective tyrosine...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics